Clinical Research News features an article on APIM's development program highlighting key attributes of the underlying mechanism of action of ATX-101 and results from the first-in-human clinical study that has been concluded with the compound. Additional insights and information on the on-going clinical studies in ovarian cancer and sarcoma are presented by APIM's CMO, Jens-Peter Marschner and APIM's CSO and NTNU Professor Marit Otterlei. A copy of the corresponding article is available here.
